Investigation of the Crust of the Pannonian Basin, Hungary Using Low-Altitude CHAMP Horizontal Gradient Magnetic Anomalies

The Pannonian Basin is a deep intra-continental basin that formed as part of the Alpine orogeny. It is some 600 by 500 km in area and centered on Hungary. This area was chosen since it has one of the thinnest continental crusts in Europe and is the region of complex tectonic structures. In order to study the nature of the crustal basement we used the long-wavelength magnetic anomalies acquired by the CHAMP satellite. The SWARM constellation, scheduled to be launched next year, will have two lower altitude satellites flying abreast, with a separation of between ca. 150 to 200 km. to record the horizontal magnetic gradient. Since the CHAMP satellite has been in orbit for eight years and has obtained an extensive range of data, both vertically and horizontally there is a large enough data base to compute the horizontal magnetic gradients over the Pannonian Basin region using these many CHAMP orbits. We recomputed a satellite magnetic anomaly map, using the spherical-cap method of Haines (1985), the technique of Alsdorf et al. (1994) and from spherical harmonic coefficients of MF6 (Maus et aI., 2008) employing the latest and lowest altitude CHAMP data. We then computed the horizontal magnetic anomaly gradients (Kis and Puszta, 2006) in order to determine how these component data will improve our interpretation and to preview what the SW ARM mission will reveal with reference to the horizontal gradient anomalies. The gradient amplitude of an 1000 km northeast-southwest profile through our horizontal component anomaly map varied from 0 to 0.025 nT/km with twin positive anomalies (0.025 and 0.023 nT/km) separated by a sharp anomaly negative at o nT/km. Horizontal gradient indicate major magnetization boundaries in the crust (Dole and Jordan, 1978 and Cordell and Grauch, 1985). Our gradient anomaly was modeled with a twodimensional body and the anomaly, of some 200 km, correlates with a 200 km area of crustal thinning in the southwestern Pannonian Basin

Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intentionto- treat population. The median age was 73 years, and the mean CHADS2 score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P<0.0001) and age 6575 years (hazard ratio 1.69, 95% CI 1.51-1.90, P<0.0001) were associated with higher all-cause mortality. Multiple additional characteristics were independently associated with higher mortality, with decreasing creatinine clearance, chronic obstructive pulmonary disease, male sex, peripheral vascular disease, and diabetes being among the most strongly associated (model C-index 0.677). Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, 487 in 10 deaths were cardiovascular, whereas <1 in 10 deaths were caused by nonhemorrhagic stroke or systemic embolism. Optimal prevention and treatment of heart failure, renal impairment, chronic obstructive pulmonary disease, and diabetes may improve survival

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo